PluriCDMO partners with Remedy Cell for IPF treatment production
HAIFA, Israel – Pluri Inc. (NASDAQ:PLUR) (TASE:PLUR), a biotechnology firm specializing in cell-based solutions, has entered a manufacturing agreement with Remedy Cell Ltd. Through its contract development and manufacturing organization (COMO) division, PluriCDMO™,the company will produce clinical-grade materials for Remedy Cell’s RC- 0315, a drug candidate aimed at treating Idiopathic Pulmonary Fibrosis (IPF). Remedy Cell,…